ESTRO 2024 - Abstract Book

S2119

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

estimated using Kaplan-Meier method. Chi-square, log-rank test and Cox model were used to test potential clinical factors related with outcome and toxicity.

Results:

One hundred and fifty-six patients were included in the final analysis, with a median age of 55 years. Most frequent tumor location were limbs (94%). Primary tumor stage at presentation was T>=3 in 71% of cases. Most frequent histotypes were liposarcoma (LPS) (34%), undifferentiated pleomorphic sarcoma (UPS) (24%) and synovial sarcoma (5%).

RT was prescribed at a total fractionated dose of 50 Gy in 25 daily fractions, which was combined with CT in 82,5 % patients. IMRT technique was used in 34% of cases.

Surgical resections were found to be R0 and R1 in 93% and 7% of patients respectively.

Major wound complications (dehiscence or sepsis) were reported in 16% of patients. Grade (G) 3 disease was reported in 69,8% patients.

With a median follow-up of 32 months, at 2 and 5 years, OS rates were 85% and 72%, DMFS rates were 69% and 57% and LC rates were 87% and 82%, respectively.

At multivariate analysis only R1 resection resulted significant for worse LC rates (p=0.0214) (fig.1), whereas G3 disease was correlated with worse DMFS (p=0.0029) (fig.2).

UPS (p=0.0028), G3 (p=0.004) and R1 (p=0.05) were correlated with worse overall survival.

All others variables tested, such as age>55, sex, site, ECOG PS, other histotypes, RT technique, t-stage, n-stage, chemotherapy, 5 days treatment suspension, radiological pd at preoperative MRI, pathological necrosis ≥ 95% didn't show any correlation with oncological outcomes.

Size >10 cm, upper arm location, use of IMRT and chemotherapy didn’t result in higher severe surgical sequelae.